That's it for today's #StopCOVIDDeaths episode!
Next week, May 13, 12pm, join us for another discussion, this time regarding boosters and latest rollout updates.
Don't miss it by registering at bit.ly/StopCOVIDDeath…
Stay safe and enjoy your weekend!
Dr. Felizarta, infectious disease expert, urges everyone to get vaccinated and boosted.
We also encourage everyone to rewatch his detailed discussion by accessing the episode via the TVUP YouTube account.
Padilla: Hopefully, very soon, this becomes seasonal
About 90% of us have some form of immunity either through vaccination, infection, or reinfection. Talagang kailangang tayong magpabakuna o kaya magpaboost na.
Padilla: After two years, we all know that we know better. We know that variants will emerge, but since we know better, we know that the evolution of the mutation is step-wise. It is now more predictable and this means that we can now have more effective vaccines.
UP goes for a second round against DLSU after the Fighting Maroons suffered a defeat at the hands of the Green Archers in the UAAP Season 84 men's basketball tournament semifinals.
Read more here: up.edu.ph/up-prepares-fo…
Question: How much is paxlovid/mulnopiravir?
For one day (taken 2x a day), around P3000-3500 per day.
You have to take that for five days, so around P15,000 for the whole course.
Villalobos: Fortunately now, it's still the corticosteriods for critical COVID, but for the others, we're still in the gray area.
He pushes for more studies for other [in-patient] treatments.
Felizarta: Paxlovid is pretty (90% decrease in hospitalization) sufficient. The only thing with it is it's still EUA--if it's fully approved, that would be better.
Congratulations to the UPIS students who received awards during the Heat Round of Philippine International Mathematical Olympiad 2022!
Click here to view the list of winners: facebook.com/OfficialUPIS/p…
Felizarta: We are not immunologically naive anymore against COVID. At least half will have hybrid immunity.
This combination of factors will prevent another major wave of deaths, that's why I'm not too concerned.
Felizarta shares some good news: [Before] The evolution of the mutations is radial, random; now, it's step-wise--it means it's becoming more predictable.
If it's predictable, we can make more effective vaccines. We want it predictable.
Dr. Felizarta recaps the epidemic curves and overall activity in the US.
"In terms of cases, the worst is Omicron; in terms of deaths, Alpha was the worst," he explains.
Up first, we have Dr. Franco Felizarta, a US-based infectious disease and internal medicine specialist, and a member of the UP Medical Alumni Association in America (UPMASA), who will discuss certain drugs of choice for home-based care.
Pinky, a security guard, recalls having heard of a drug as treatment against COVID, but upon checking, seemed to be quite expensive.
"Kung may pera lang, kayang bilhin, kaya," she says.
Today's hosts are Dr. Raymond Francis Sarmiento, Director of the National Institutes of Health (NIH), National Telehealth Center (NTC), and Dr. Susan Pineda Mercado, Adjunct Faculty at UP Manila-NTC.
However, not all countries have access to these drugs.
Join us as we learn about the latest anti-viral drugs and how treatment plays a critical role in controlling the pandemic. (2/2)
The World Health Organization (WHO) recently made a strong recommendation for using nirmatrelvir and ritonavir—sold under the name Paxlovid—to treat mild and moderate COVID-19 patients at the highest risk of hospital admission. (1/2)